生物追踪器ASCO事件列表

Event DateDrug2025-06-01Aucatzyl2025-05-30Iclusig2025-06-02Ziftomenib2025-06-02Lisaftoclax2025-06-01Rezlidhia2025-05-30FP-13052025-05-30RC10122025-05-22Lisaftoclax2025-05-22ICT012025-05-22Inqovi2025-05-22Ziftomenib2025-05-22Rezlidhia2025-05-22Azacitidine 2025-06-03NXC-2012025-05-31Zynyz2025-05-31Zynyz2025-05-22GNTbm-382025-05-31Ziihera2025-05-31FF-108322025-06-02Zelenectide Pevedotin2025-06-02Keytruda2025-06-02Keytruda2025-06-02VesiGel2025-06-02Padcev2025-06-02Sasanlimab2025-06-02BH0112025-06-01Keytruda2025-06-01Opdivo2025-06-01Padcev2025-06-01M62232025-06-01Keytruda2025-06-01Imfinzi2025-06-01Bavencio2025-06-01Trodelvy2025-06-01Yervoy2025-05-31bulumtatug fuvedotin2025-05-31Tookad2025-05-30AdstiladrinAngioimmunoblastic T-Cell Lymphoma (AITL) - NHLBiliary Tract CancerBladder CancerList of BiAcute Lymphoblastic Leukemia (ALL)Acute Myelogenous Leukemia (AML)Amyloid light-chain (AL) AmyloidosisAnal Cancer2025-05-30BH0112025-05-30VesiGel2025-05-30Disitamab Vedotin2025-05-30RAG-012025-05-23Sasanlimab2025-06-01Elzonris2025-06-01Elzonris2025-05-27Pivekimab2025-06-02SHR-20172025-06-02ONC2012025-06-02KROS-1012025-06-01IL13 Ra2 CAR-T Program (Tmunity)2025-05-31ST101 (Sapience)2025-05-31Azeliragon2025-05-31Ojemda2025-05-31Azeliragon2025-05-30INB-2002025-05-30BXQ-3502025-05-30IVS-10012025-05-30Dubodencel2025-05-30Pemazyre2025-05-30Anlotinib2025-05-31Utidelone2025-06-02TQB-21022025-06-02INO-54012025-06-02SCR68522025-06-02TQB-21022025-06-02IBI3542025-05-30FWD18022025-06-02TQB21032025-06-02DK210 2025-06-02TACH1012025-06-03Cadonilimab2025-06-02BAT 1308 2025-06-02TG40012025-06-01VB10.162025-06-01Loqtorzi2025-06-01SG0012025-05-23ATG-008Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHLBrain Cancer (Malignant Glioma; AA and glioblastoma (GBM))Brain Cancer (Secondary; Metastases)Breast CancerCancerCervical CancerBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Bone Complications (Including Bone Metastases)2025-06-01Breyanzi2025-06-01Imbruvica2025-05-31Brukinsa2025-05-31Brukinsa2025-05-30Brukinsa2025-05-26DZD-85862025-06-02Scemblix2025-05-31Scemblix2025-05-30Scemblix2025-05-22Azacitidine 2025-06-02SLS-0092025-06-02Balstilimab2025-06-02precemtabart tocentecan2025-06-02Petosemtamab2025-06-01IBI-3632025-06-01Stivarga2025-06-01JMT1012025-06-01DSP1072025-06-01Tecentriq2025-05-31IN-100182025-05-31Vilastobart2025-05-31ONO-45782025-05-31Rybrevant2025-05-31D-15532025-05-31Keytruda2025-05-31GCC19CART2025-05-31Azenosertib2025-05-31EO40102025-05-30Lumakras2025-05-30Fruzaqla2025-05-30Olomorasib2025-05-30Opdivo2025-05-30Yervoy2025-05-30Braftovi2025-05-23Vectibix2025-05-22Olomorasib2025-05-22Vilastobart2025-05-22ADG1262025-05-22Keytruda2025-05-23Lacutamab2025-06-02AL1022025-05-31AL1022025-06-01Epkinly2025-06-01TNB-486Desmoid TumorsDiffuse Large B-Cell Lymphoma (DLBCL) - NHLChronic Myelogenous Leukemia (CML)Chronic Myelomonocytic Leukemia (CMML)Colorectal Cancer (CRC)Cutaneous T-Cell Lymphoma (CTCL) - NHL2025-05-30VLS-1012025-05-30KITE-3632025-05-30DZD-8

立即下载
综合
2025-06-17
60页
1.71M
收藏
分享

生物追踪器ASCO事件列表,点击即可下载。报告格式为PDF,大小1.71M,页数60页,欢迎下载。

本报告共60页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共60页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
图 5 2024 年全国各地区起降架次(不含香港特别行政区、澳门特别行政区和台湾地区)
综合
2025-06-17
来源:2024年全国民航航班运行效率报告-民航局运行监控中心
查看原文
2024 年城投投资现金流出进一步放缓 图 31:重点省份投资现金流出更为审慎
综合
2025-06-17
来源:从财务视角看化债与转型背景下的城投企业——基于对2390家城投企业2024年年报的分析
查看原文
城投企业收现比改善但 ROA 持续下降 图 29:重点省份城投企业收现比与 ROA
综合
2025-06-17
来源:从财务视角看化债与转型背景下的城投企业——基于对2390家城投企业2024年年报的分析
查看原文
2024 年城投企业非标规模及占比“双压降” 图 25:重点省份城投企业短债占比压降明显
综合
2025-06-17
来源:从财务视角看化债与转型背景下的城投企业——基于对2390家城投企业2024年年报的分析
查看原文
31 省城投债发行利差均下降,12 个重点省份下行幅度较大但绝对数值仍然偏高
综合
2025-06-17
来源:从财务视角看化债与转型背景下的城投企业——基于对2390家城投企业2024年年报的分析
查看原文
13 省城投企业融资成本同比下降,重点省份融资成本依然偏高
综合
2025-06-17
来源:从财务视角看化债与转型背景下的城投企业——基于对2390家城投企业2024年年报的分析
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起